Hippocrates Research Swiss
The Boutique CRO Advantage: A High-Value Alternative
In today’s clinical landscape, where capital efficiency and hands-on expertise are the primary drivers for Biotech and Medtech companies, Hippocrates Research Swiss stands as a robust alternative to multinational CROs, building on thirty years of experience of the Hippocrates Group. We transform scientific innovation into solid clinical assets through a leaner, more agile, and highly specialised approach.
Our Core Strengths
- Proven Authority: a 30-year uninterrupted track record of success in Phase I First-in-Human (FIH) and First-in-Class trials. We manage product development from Phase I through Phase III, backed by peer-reviewed publications.
- Real Financial Efficiency: an optimised cost structure with significantly lower overhead than “Big CROs”. This allows sponsors to allocate more resources to science and less to administration, ensuring a premium cost-to-benefit ratio.
- Team Seniority & Continuity: we eliminate the “revolving door” turnover typical of large CROs. Your project will not be handed over to junior staff after contract signature. Every trial is managed by experts with 15 to 30 years of real-world experience.
- 2026 Innovation Readiness: agility in implementing Decentralised Clinical Trials (DCTs) via our HomeTrial 360® platform and predictive AI for recruitment. We leverage validated technologies to bring the trial to the patient, enhancing recruitment and retention while reducing site burden.
- Predictive AI Recruitment: we integrate advanced analytics to identify high-potential investigative sites, ensuring timelines are met and minimising unnecessary activation costs.
Your Value Accelerator
Hippocrates Group is more than a service provider; we are a value accelerator for innovative companies.
- Multidisciplinary Expertise: specialised in managing complex protocols—from Rare Diseases and Oncology to high-tech Medical Devices (Medtech).
- Regulatory Mentoring: we don’t just follow the rules; we help you navigate them. We provide strategic support for accelerated pathways (PRIME, Orphan Drug, Breakthrough Therapy) to shorten time-to-market.
- Total Transparency (Real-Time Data): constant access to study data and KPIs. We eliminate the “black box” approach, giving sponsors full control over progress at all times.
- Strategic Pan-European Hub: a pan-European presence with a strong focus on Switzerland and Italy, providing privileged access to leading European investigators and deep expertise in EMA, FDA, and local regulatory requirements.
- Flexible Collaboration Models: from integrated regulatory consulting to Functional Service Provider (FSP) models, we scale alongside your company’s growth.
Conclusion
In a market where every month of delay costs millions, Hippocrates Group provides the certainty of a solid, expert, and financially sustainable partner. We bring thirty years of clinical success to your side to turn innovation into therapeutic reality.
Hippocrates Group: three decades of stability, the agility of the future.
Value Drivers Comparison
| KPI | International CROs | Hippocrates Group | Impact on the Study/Fund ROI |
| Annual Staff Turnover | 25% – 35% | < 2,6 % | Prevents 2-3 month delays if the team that starts the study finishes it. |
| Admin & Overhead | 40% – 60% of budget | 15% – 20% of budget |
Maximizes “Dollars to Science”. Lean Efficiency: competitive rates focused on clinical value. |
| Operational Seniority | 3-5 years (Junior) | 15-30 years (Senior) | Drastic reduction in risk, Project Team led by experts with 15-30 years of experience. |
| Budget Drift | +20% to +40% (Change Orders) |
< 5% (Scope based) |
Protects the financial runway, real-time response and immediate adaptability. |
| Site Activation | 4-6 months | 2-3 months (AI Driven) |
Faster time-to-market: digital trials, remote monitoring, and Predictive AI. |
|
KPI Annual Staff Turnover International CROs 25% – 35% Hippocrates Group < 2,6 % Impact on the Study/Fund ROI Prevents 2-3 month delays if the team that starts the study finishes it. |
|
KPI Admin & Overhead International CROs 40% – 60% of budget Hippocrates Group 15% – 20% of budget Impact on the Study/Fund ROI Maximizes “Dollars to Science”. Lean Efficiency: competitive rates focused on clinical value.
|
|
KPI Operational Seniority International CROs 3-5 years (Junior) Hippocrates Group 15-30 years (Senior) Impact on the Study/Fund ROI Drastic reduction in risk, Project Team led by experts with 15-30 years of experience. |
|
KPI Budget Drift International CROs +20% to +40% (Change Orders) Hippocrates Group < 5% (Scope based) Impact on the Study/Fund ROI Protects the financial runway, real-time response and immediate adaptability. |
|
KPI Site Activation International CROs 4-6 months Hippocrates Group 2-3 months (AI Driven) Impact on the Study/Fund ROI Faster time-to-market: digital trials, remote monitoring, and Predictive AI. |
- BDO USA, LLP: 2023-2024 CRO Industry Survey (Benchmark su turnover e compensi).
- Tufts Center for the Study of Drug Development (CSDD): Cost of Protein Drug Development e Impact Analysis of Protocol Amendments.
- ISR Reports (Industry Standard Research): CRO Quality Benchmarking Reports.
- CenterWatch: Analysis of Clinical Trial Delays and Recruitment Challenges.
- SEC Filings (10-K Reports): Analisi dei margini operativi dei competitor multinazionali quotati.